Clinical Trial

Evaluate Pharmacokinetics, Safety, and Tolerability of AX251 LAI in Patients With Schizophrenia

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of AX251 long-acting injectable (LAI) administered as a single dose in patients with schizophrenia. The study will include sequential dose-escalation cohorts to evaluate different dose levels of AX251 LAI.
Protocol Amendment History 1 change
notable Trial sites expanded: 1 -> 4 locations 2026-07-23
Trial Details
NCT Number NCT07484204
Lead Sponsor Anxo Pharmaceutical Co., Ltd.
Conditions Schizophrenia
Enrollment 48 participants
Start Date 2026-07
Primary Completion 2028-07 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-22